Study guide

5.4 Paracetamol & Salicylate Poisoning

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

5.4 Paracetamol & Salicylate Poisoning

Key Takeaways Explain This Topic AI

Acetylcysteine is given when the 4-hour or later paracetamol level is on or above the single 100 mg/L nomogram treatment line, and immediately in staggered or unknown-time overdose.

King's College criteria for paracetamol-induced acute liver failure are arterial pH below 7.30, or the triad of INR above 6.5, creatinine above 300 micromol/L and grade III-IV encephalopathy.

Salicylate poisoning causes early respiratory alkalosis then high anion gap metabolic acidosis; haemodialysis is indicated above about 700 mg/L or for acidosis, renal failure or altered consciousness.

Last updated: September 2026

Note

Curriculum Focus : The MRCP(UK) Part 1 examination rigorously tests acute poisoning emergencies. Candidates must master paracetamol metabolism, UK TOXBASE management nomograms, King's College liver transplantation criteria, mixed acid-base disorders in salicylate poisoning, rapid toxidrome recognition, carbon monoxide and cyanide rescue protocols, and toxic alcohol diagnostics.

Acute poisoning constitutes approximately 1% of all UK emergency department attendances. Systematic management rests upon rapid physiological stabilisation (Airway, Breathing, Circulation), toxidrome recognition, diagnostic acid-base and osmolar analysis, and prompt administration of targeted antidotes.

Paracetamol Hepatotoxicity & Acute Liver Failure

Paracetamol (acetaminophen) is the most common pharmaceutical agent involved in intentional self-poisoning in the United Kingdom. +-----------------------------------------------------------------------------------------+

  • | Paracetamol Hepatic Metabolism Pathways |
  • +-----------------------------------------------------------------------------------------+
  • | [ PARACETAMOL ] |
  • | | | | |
  • | Glucuronidation (~55%) Sulfation (~30%) CYP2E1 Oxidation (~5-10%) |
  • | | | | |
  • | v v v |
  • | [ Non-Toxic Metabolites ] [ NAPQI ] (Highly Reactive) |
  • | | |
  • | +--------------+--------------+ |
  • | | (Normal Stores) | (Depletion) |
  • | v v |
  • | [ Glutathione ] Centrilobular Necrosis |
  • | | (Zone 3) Hepatotoxicity|
  • | v |
  • | [ Mercapturic Acid ] |
  • +-----------------------------------------------------------------------------------------+
  • Pathophysiology

At therapeutic doses, over 85% of paracetamol is safely conjugated via glucuronidation and sulfation into non-toxic metabolites excreted in urine. A small fraction (5–10%) is oxidised by CYP2E1 into the highly electrophilic, toxic intermediate N-acetyl-p-benzoquinone imine (NAPQI) .

Under normal conditions, NAPQI is instantaneously detoxified by conjugation with hepatic glutathione to form non-toxic cysteine and mercapturic acid conjugates.

In acute overdose, the primary sulfation and glucuronidation pathways saturate. CYP2E1 oxidation shunts an enormous burden of paracetamol into NAPQI formation. Once hepatic glutathione stores are depleted by > 70% , free unconjugated NAPQI binds covalently to cysteinyl sulfhydryl groups on hepatocellular proteins and mitochondrial membranes. This initiates oxidative stress, mitochondrial permeability transition pore opening, ATP depletion, and fulminant centrilobular (Zone 3) hepatic necrosis .

UK TOXBASE Management Guidelines

Nomogram Utility : Plasma paracetamol concentration must be timed against the single treatment line on the UK TOXBASE nomogram, which starts at 100 mg/L at 4 hours post-ingestion (extrapolating to 15 mg/L at 16 hours). Samples drawn prior to 4 hours post-ingestion cannot be interpreted due to ongoing gastrointestinal absorption.

Treatment Timeline :

Presentation < 8 hours : Draw bloods at exactly 4 hours post-ingestion. If concentration is on or above the treatment line, initiate N-acetylcysteine (NAC) . Ingestion presenting < 8 hours carries virtually zero risk of hepatic necrosis if NAC is started within 8 hours.

Presentation 8–24 hours : Start intravenous NAC immediately without waiting for laboratory results. If subsequent paracetamol level is below the line, ALT is normal, and patient is asymptomatic, NAC can be stopped.

Presentation > 24 hours or Staggered Overdose : In a staggered overdose (tablets taken over an interval > 1 hour), the nomogram cannot be used. Commence IV NAC immediately regardless of the paracetamol level.

Intravenous N-Acetylcysteine (NAC) Protocols

NAC acts as a synthetic glutathione precursor by supplying cysteine, replenishing intracellular glutathione reserves, and directly binding free NAPQI. In late-presenting acute liver failure, NAC additionally improves microcirculatory perfusion, oxygen delivery, and cerebral oedema via free radical scavenging.

Traditional 21-Hour Regimen : 3-bag infusion (150 mg/kg over 1h, 50 mg/kg over 4h, 100 mg/kg over 16h; total 300 mg/kg).

Simplified 12-Hour Regimen (SNAP Regimen) : Increasingly standard in UK emergency departments: 100 mg/kg over 2 hours, followed by 200 mg/kg over 10 hours. Halves the infusion time and drastically reduces adverse events.

Anaphylactoid Reactions to NAC : Up to 15% of patients experience a non-IgE-mediated anaphylactoid reaction (histamine release causing erythema, flushing, pruritus, urticaria, or mild wheezing), predominantly during the initial rapid loading infusion. Management : Do NOT permanently discontinue NAC. Temporarily halt the infusion, administer IV chlorphenamine, give nebulised salbutamol if bronchospastic, and restart the NAC infusion at a reduced rate once symptoms resolve.

King's College Hospital Criteria for Liver Transplantation

These criteria identify patients with acute liver failure who have a > 85% predicted mortality without emergency orthotopic liver transplantation: +------------------------------------------------------------------------------------------+

  • | King's College Criteria for Liver Transplantation |
  • +------------------------------------------------------------------------------------------+
  • | PARACETAMOL-INDUCED ACUTE LIVER FAILURE: |
  • | |
  • | Arterial Blood pH < 7.30 (sampled >= 24h post-ingestion, following fluid resuscitation) |
  • | -- OR -- |
  • | ALL THREE of the following clinical parameters occurring within a 24-hour window: |
  • | 1. International Normalised Ratio (INR) > 6.5 (Prothrombin Time > 100 seconds) |
  • | 2. Serum Creatinine > 300 umol/L (3.4 mg/dL) |
  • | 3. Hepatic Encephalopathy Grade III (somnolent, confused) or Grade IV (coma) |
  • | |
  • | *Note: Arterial lactate > 3.0 mmol/L at 12h or > 3.5 mmol/L at 4h after resuscitation |
  • | is also a strong independent indicator for urgent transplant listing. |
  • +------------------------------------------------------------------------------------------+
  • Salicylate (Aspirin) Poisoning

Salicylates exhibit complex toxicity characterised by a signature mixed acid-base disturbance :

Pathophysiology

Direct Medullary Stimulation (Early) : Salicylates directly stimulate the respiratory centre in the brainstem medulla oblongata, driving hyperventilation and causing a primary respiratory alkalosis (pCO2 decreased, pH elevated).

Uncoupling of Mitochondrial Oxidative Phosphorylation (Late) : Salicylates disrupt the mitochondrial proton gradient, halting ATP synthesis while oxygen consumption and heat generation escalate. Cells shift to anaerobic glycolysis, generating massive amounts of lactic acid and pyruvic acid. Additionally, enhanced lipolysis produces ketoacids, while salicylate molecules contribute exogenous unmeasured anions, establishing a high anion gap metabolic acidosis (HAGMA) .

Classic Acid-Base Blood Gas Profile : In adults, arterial blood gas typically demonstrates a combined primary respiratory alkalosis with a primary high anion gap metabolic acidosis (e.g., normal or near-normal pH, low pCO2, markedly low HCO3-, high anion gap).

Clinical Presentation & Management

Symptoms : Tinnitus (classic early sign, due to altered cochlear microvascular blood flow), sensorineural deafness, hyperpnoea (Kussmaul-like breathing), pyrexia, profuse sweating, nausea, vomiting, confusion, seizures, non-cardiogenic pulmonary oedema, and cardiovascular collapse.

Urinary Alkalinisation : Salicylic acid has a pKa of 3.0. In an acidic environment, it remains non-ionised, diffusing freely across renal tubular membranes back into the bloodstream. Administering intravenous 1.26% or 8.4% sodium bicarbonate alkalinises the renal tubular fluid (target urine pH = 7.5 - 8.5). Under alkaline conditions, salicylic acid dissociates into its ionised, charged salicylate form, which cannot cross lipophilic tubular membranes and is trapped in urine ( ion trapping ), increasing renal excretion up to 20-fold.

Prerequisite : Must aggressively correct hypokalaemia before alkalinisation will succeed. If hypokalaemia is present, renal intercalated cells will excrete hydrogen ions into the tubular lumen via the H+/K+ ATPase to conserve potassium, rendering urine stubbornly acidic despite systemic alkalaemia.

Indications for Emergency Haemodialysis :

Plasma salicylate level > 700 mg/L (5.1 mmol/L) in acute overdose.

Refractory severe metabolic acidosis (pH < 7.20).

Severe neurological manifestations (seizures, coma, altered mental state).

Acute kidney injury or acute pulmonary oedema (preventing fluid/bicarbonate administration).